CurifyLabs, founded in Helsinki in 2021 by Charlotta Topelius and Niklas Sandler Topelius, makes machines inspired by 3D printing that let pharmacies prepare personalised doses of medicines, such as for children or older patients whose needs standard tablets do not meet. It was selected in the EIC Accelerator's January 2023 cut-off and received an EU grant of €2.48 million for PMed, a €3.54 million project that ran from September 2023 to August 2025, according to CORDIS. The aim was to make its system scalable across therapeutic areas.
The project is closed. Its final report states that CurifyLabs created six new excipient premixes enabling printable formulations for fifty new active ingredients, "exceeding initial targets", cut formulation lead times from several months to one to two months, built a library of more than 70 validated formulations and gained ISO 13485 certification in June 2024, according to the CORDIS reporting page. In July 2026 the company closed a $14 million Series A and said pharmacies in 21 US states and across Europe use its technology "to compound and dispense thousands of doses every day", according to PR Newswire.
Company file
- Legal entity
- CurifyLabs Oy, business ID 3183859-4, Helsinki
- CEO and founder
- Charlotta Topelius
- Products
- PharmaPrinter Aurum, PharmaPrinter 01, excipient bases, software
- Investors named
- Sandwater, HealthCap, Tesi, Lifeline Ventures, Springvest
- US dateline
- Jacksonville, Florida, per 2026 release
- Staff
- 21 in 2025
- EIC funding
- Grant first
Where CurifyLabs Stands Now
The Series A was co-led by Sandwater and HealthCap, with the Finnish state investor Tesi and existing investors including Lifeline Ventures; US customers and employees also took part. Proceeds will fund US operations, supply chains and customer support. In May 2025 the company raised €6.7 million, led by Springvest and including a €1 million deep tech loan from Business Finland, and announced RoboPharma, an EU project worth €5.6 million in total, according to its press release.
"Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage."
Joni Karsikas, investment director, Tesi, July 2026The Technology: Compounding by Machine
When a patient needs a dose or form that is not sold commercially, pharmacists compound it by hand. CurifyLabs' system combines ready-made excipient bases, a printer that deposits each dose, a precision scale that weighs every printed dose, and cloud software with audit trails designed to meet EU Annex 11 and US 21 CFR Part 11 rules. Its latest PharmaPrinter Aurum compounds "up to nine times faster than manual processes", the company says.
What the EIC Award Promised, and What the Record Shows
The award promised to make patient-specific medicines practical in hospitals and pharmacies. The final report records targets met or exceeded, and the commercial record backs it: revenue grew from €161,000 in 2023 to €1.19 million in 2025, and the system is in daily use on two continents.
- New printable formulationsDelivered50 new APIs.
- Integrated quality controlDelivered100% dose weighing.
- CertificationDeliveredISO 13485, 2024.
- Automated NIR checksPartialPrototype models.
The Money
CurifyLabs' operating loss rose from €1.33 million in 2024 to €4.42 million in 2025, while staff grew to 21, according to Asiakastieto. Private investors put in €6.7 million in 2025 and about €12 million in 2026, according to EU-Startups, several times the EIC grant.
What Cannot Be Checked
Questions for the EIC
How much of CurifyLabs' revenue comes from Europe rather than the US, how many hospitals use it, and whether EU patients benefit as much as American ones are not public.
Why Europe Should Care
The EIC funded a Finnish technology that works and sells. The first stated use of the new money is expanding US operations, and the Finnish state investor Tesi hailed the company's US growth. How much of its use is in Europe, where the EU grant came from, is not public.
What the award promised
A scalable way to make patient-specific medicines in hospitals and pharmacies.
What the record shows
Targets exceeded, a certified system in daily use, sales doubling yearly and $14 million of new capital.
The Verdict
A grant that paid off
CurifyLabs delivered what the EIC funded and has private investors backing its growth. The test now is whether rising losses turn into a profitable business.
CurifyLabs and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
